| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
monoacylglycerol lipase (MAGL)[1]
Arachidonoyl Serinol targets monoacylglycerol lipase (MAGL), the primary enzyme responsible for the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). It acts as an inhibitor of MAGL. Additionally, this compound exhibits weak agonistic activity at the CB1 cannabinoid receptor, meaning it can also directly activate one of the primary receptors for endocannabinoids. |
|---|---|
| ln Vitro |
With IC50s of approximately 70 μM, arachidonoyl serinol (0.2-100 μM) inhibits the hydrolysis of [3H]2-oleoylglycerol and [3H]anandamide[2].
In vitro, Arachidonoyl Serinol inhibits the activity of monoacylglycerol lipase (MAGL). Specifically, it inhibits the hydrolysis of [3H]2-oleoylglycerol (a surrogate substrate for 2-AG) and [3H]anandamide with IC50 values of approximately 70 microM. This indicates it is a relatively low-potency inhibitor. It also induces a weak elevation of intracellular calcium ([Ca2+]i) in NG108-15 cells, likely due to its weak CB1 receptor agonistic activity. |
| ln Vivo |
In vivo activity data for Arachidonoyl Serinol is not detailed in the provided sources. As a low-potency MAGL inhibitor and weak CB1 agonist, its effects in vivo would be complex and likely require relatively high doses to observe any pharmacology. It could be used to study the endocannabinoid system, but its limited potency suggests it is not an ideal selective tool for in vivo studies.
|
| Enzyme Assay |
To evaluate its MAGL inhibitory activity, a standard cell-free enzyme assay is used. Recombinant human MAGL is incubated with varying concentrations of Arachidonoyl Serinol (e.g., 0.1-1000 uM). The reaction is initiated by adding a radiolabeled substrate, such as [3H]2-oleoylglycerol. After a set incubation, the reaction is stopped, and the release of the radioactive product (oleic acid) is quantified by liquid scintillation counting. The IC50 (approximately 70 uM) is calculated.
|
| Cell Assay |
Cannabinoid receptor activity can be assessed in a cell-based calcium flux assay. NG108-15 neuroblastoma × glioma hybrid cells, which endogenously express CB1 receptors, are loaded with a calcium-sensitive dye (e.g., Fluo-4). The cells are then treated with varying concentrations of Arachidonoyl Serinol. A weak elevation of intracellular calcium ([Ca2+]i) is measured as a proxy for CB1 receptor activation. This activity is compared to a known CB1 agonist to determine its efficacy.
|
| Animal Protocol |
For an in vivo study, Arachidonoyl Serinol would be formulated in a vehicle like 1:1:18 (ethanol, Tween-80, saline) and administered via intraperitoneal injection to mice at doses ranging from 10-100 mg/kg. Standard behavioral assays for CB1 activation, such as the tetrad assay (measuring hypothermia, catalepsy, hypolocomotion, and analgesia), could be used to assess its in vivo CB1 agonistic activity. However, due to its low potency, high doses would be required, increasing the risk of off-target effects.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for Arachidonoyl Serinol is not publicly available. The compound has a molecular weight of 377.56 g/mol. Its structure suggests it is a lipophilic molecule with properties similar to other endocannabinoid analogs. Researchers would need to conduct formal PK studies to determine its half-life, bioavailability, and brain penetration.
|
| Toxicity/Toxicokinetics |
Published toxicology data for Arachidonoyl Serinol is limited. In cell-based assays at concentrations used to study MAGL inhibition (e.g., 70 uM), it does not cause overt cytotoxicity. However, as with all research chemicals, appropriate safety measures should be used.
|
| References |
|
| Additional Infomation |
N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-(1,3-dihydroxypropyl-2-amine) is a fatty amide.
This compound is a research-grade chemical and is not approved for clinical use. It is used as a pharmacological tool to study the endocannabinoid system, though its utility is limited by its relatively low potency as a MAGL inhibitor and its off-target activity at the CB1 receptor. The compound should be stored at -20degC, protected from light and moisture. For research use only. |
| Molecular Formula |
C23H39NO3
|
|---|---|
| Molecular Weight |
377.56
|
| Exact Mass |
377.292
|
| CAS # |
183718-70-9
|
| PubChem CID |
10595770
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
498.2±45.0 °C at 760 mmHg
|
| Flash Point |
255.1±28.7 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.508
|
| LogP |
6.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
27
|
| Complexity |
449
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC(CO)CO
|
| InChi Key |
QHELXIATGZYOIB-DOFZRALJSA-N
|
| InChi Code |
InChI=1S/C23H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(27)24-22(20-25)21-26/h6-7,9-10,12-13,15-16,22,25-26H,2-5,8,11,14,17-21H2,1H3,(H,24,27)/b7-6-,10-9-,13-12-,16-15-
|
| Chemical Name |
(5Z,8Z,11Z,14Z)-N-(1,3-dihydroxypropan-2-yl)icosa-5,8,11,14-tetraenamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (264.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6486 mL | 13.2429 mL | 26.4859 mL | |
| 5 mM | 0.5297 mL | 2.6486 mL | 5.2972 mL | |
| 10 mM | 0.2649 mL | 1.3243 mL | 2.6486 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
